Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation

Platinum‐based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to ch...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Xiaoliang Zhao, In‐Kyu Kim, Bhaskar Kallakury, Joeffrey J. Chahine, Eiji Iwama, Mariaelena Pierobon, Emanuel Petricoin, Justine N. McCutcheon, Yu‐Wen Zhang, Shigeki Umemura, Vincent Chen, Changli Wang, Giuseppe Giaccone
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2021-04-01
Serija:	Molecular Oncology
Teme:	acquired resistance cell cycle Chk1 inhibitor Wee1
Online dostop:	https://doi.org/10.1002/1878-0261.12882
Oznake:	Označite Brez oznak, prvi označite!